Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) had its target price raised by HC Wainwright from $7.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.
Several other equities analysts have also issued reports on the company. D. Boral Capital reduced their target price on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Craig Hallum assumed coverage on Lineage Cell Therapeutics in a report on Tuesday, August 20th. They issued a “buy” rating and a $4.00 target price for the company.
Get Our Latest Stock Report on LCTX
Lineage Cell Therapeutics Price Performance
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in Lineage Cell Therapeutics in the third quarter valued at $46,000. XTX Topco Ltd bought a new position in shares of Lineage Cell Therapeutics during the second quarter valued at about $61,000. GSA Capital Partners LLP bought a new position in shares of Lineage Cell Therapeutics during the third quarter valued at about $84,000. Rhumbline Advisers grew its stake in shares of Lineage Cell Therapeutics by 15.1% during the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock valued at $132,000 after buying an additional 17,411 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of Lineage Cell Therapeutics by 311.3% during the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock valued at $192,000 after buying an additional 159,924 shares during the last quarter. Institutional investors own 62.47% of the company’s stock.
About Lineage Cell Therapeutics
Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
See Also
- Five stocks we like better than Lineage Cell Therapeutics
- Stock Analyst Ratings and Canadian Analyst Ratings
- Tesla Poised to Hit Record Highs This Holiday Season
- Using the MarketBeat Dividend Yield Calculator
- The Salesforce Rally is Just Getting Started: Here’s Why
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Chip and Data Center Stocks That Can Keep Rising in 2025
Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.